Archives

by in
Entry Author Date Location
Some Bold Baseball and Biotech Picks for the 2013 Season 03/11/13 National
Genentech, ImmunoGen Win FDA OK for Souped-Up Breast Cancer Drug 02/22/13 San Francisco
Blaze Bioscience Caps Off $8.5M Financing, Charges Toward Clinic 02/22/13 Seattle
Seattle Genetics Gets $138M in First-Year Sales of Cancer Drug 02/12/13 Seattle
Seattle Genetics, Millennium Cancer Drug Cleared in EU 10/31/12 Seattle
Seattle Genetics Gets $25M in Broader Abbott Deal 10/23/12 Seattle
Seattle Genetics Gets $34.7M in Second-Quarter Sales of Cancer Drug 08/08/12 Seattle
Seattle Genetics, Millennium Get EU Recommendation for Lymphoma Drug 07/20/12 Seattle
Life Science Innovation NW Notes: SeaGen, NanoString, Viket, & More 07/12/12 Seattle
NanoString Nabs Ex-Seattle Genetics Exec to Lead Diagnostic Push 05/29/12 Seattle
Seattle Genetics Follows the Science, Taking on Rare Lymphoma No. 3 05/23/12 Seattle
Targeted Cancer Drugs With Punch: The Next Big Class of Antibodies 05/16/12 National
Seattle Genetics Misses 1st Quarter Sales Estimate, But Sees $1B Future 05/08/12 Seattle
Seattle Genetics Digs Deeper Into the Proverbial Haystack 03/13/12 National
Seattle Genetics Gets New Commercial Boss for Early Days of Adcetris 02/23/12 Seattle
Seattle Genetics, Millennium Look to Broaden Reach of Hodgkin’s Drug 12/09/11 Seattle
Seattle Genetics Beats Expectations With $10M Sales in Lymphoma Drug Debut 11/03/11 Seattle
TEDMED Walking, FDA Clears Pacira Drug, Zogenix Close to NDA, & More San Diego Life Sciences News 11/03/11 San Diego
The Cancer Drug Dark Ages Are Coming to an End 10/31/11 National
Analyst: Seattle Genetics on Pace to Smash Wall Street Forecast with Lymphoma Drug Rollout 10/20/11 Seattle
Seattle Genetics’ Market Debut, Pathway Gets Bought, Theraclone’s Latest Trick Against HIV, & More Seattle-Area Life Sciences News 08/25/11 Seattle
Video: Seattle Genetics CEO Makes the Case for a $100K Cancer Drug 08/22/11 Seattle
Seattle Genetics Sets Lymphoma Drug Price at $13,500 Per Dose 08/22/11 Seattle
Seattle Genetics: The Next Litmus Test for High Priced Cancer Drugs 08/22/11 National
Seattle Genetics Wins FDA Approval of First Drug, a New Treatment for Lymphomas 08/19/11 Seattle
SeaGen Passes FDA Panel, Ken Stuart’s Journey to Seattle Biomed, the Latest M&A Obsession, & More Seattle-Area Life Sciences News 07/21/11 Seattle
Stop the M&A Obsession: Biotech Needs More Companies to Stay Independent 07/18/11 National
Seattle Genetics Lymphoma Drug Gets Second Green Light from FDA Panel 07/14/11 Seattle
Seattle Genetics Wins Unanimous OK for Lymphoma Drug from FDA Panel 07/14/11 Seattle
SeaGen’s Big Day at the FDA, Hutch Nabs $20M HIV Grant, Allozyne’s Nasdaq Plan, & More Seattle-Area Life Sciences News 07/14/11 Seattle
Page 1 of 2 next page »